Skip to main content
SpringerLink
Log in

Nichtkleinzelliges Lungenkarzinom

Zusätzliche MET-Inhibition in der Zweitlinientherapie

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Originalie

  • Scagliotti G et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(24):2667-74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onkologische Schwerpunktpraxis München, München, Deutschland

    Andreas Schalhorn

Authors
  1. Andreas Schalhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Schalhorn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schalhorn, A. Zusätzliche MET-Inhibition in der Zweitlinientherapie. Info Onkol. 19, 21–22 (2016). https://doi.org/10.1007/s15004-016-5337-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-016-5337-5

Schlüsselwörter

Search

Navigation